Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cellect Biotechnology stock

Own Cellect Biotechnology stock in just a few minutes.

Fact checked

Cellect Biotechnology Ltd is a biotechnology business based in the US. Cellect Biotechnology shares (APOP) are listed on the NASDAQ and all prices are listed in US Dollars. Cellect Biotechnology employs 14 staff and has a market cap (total outstanding shares value) of USD$14.3 million.

How to buy shares in Cellect Biotechnology

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Cellect Biotechnology. Find the stock by name or ticker symbol: APOP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cellect Biotechnology reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cellect Biotechnology, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Cellect Biotechnology. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cellect Biotechnology share price

Use our graph to track the performance of APOP stocks over time.

Cellect Biotechnology shares at a glance

Information last updated 2021-02-23.
52-week rangeUSD$0.4 - USD$4.34
50-day moving average USD$3.1885
200-day moving average USD$2.4572
Wall St. target priceUSD$12
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.854

Buy Cellect Biotechnology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cellect Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cellect Biotechnology financials

Gross profit TTM USD$0
Return on assets TTM -37.99%
Return on equity TTM -99.63%
Profit margin 0%
Book value $0.691
Market capitalisation USD$14.3 million

TTM: trailing 12 months

Shorting Cellect Biotechnology shares

There are currently 24,854 Cellect Biotechnology shares held short by investors – that's known as Cellect Biotechnology's "short interest". This figure is 54.6% down from 54,694 last month.

There are a few different ways that this level of interest in shorting Cellect Biotechnology shares can be evaluated.

Cellect Biotechnology's "short interest ratio" (SIR)

Cellect Biotechnology's "short interest ratio" (SIR) is the quantity of Cellect Biotechnology shares currently shorted divided by the average quantity of Cellect Biotechnology shares traded daily (recently around 191184.61538462). Cellect Biotechnology's SIR currently stands at 0.13. In other words for every 100,000 Cellect Biotechnology shares traded daily on the market, roughly 130 shares are currently held short.

However Cellect Biotechnology's short interest can also be evaluated against the total number of Cellect Biotechnology shares, or, against the total number of tradable Cellect Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cellect Biotechnology's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Cellect Biotechnology shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Cellect Biotechnology shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cellect Biotechnology.

Find out more about how you can short Cellect Biotechnology stock.

Cellect Biotechnology share dividends

We're not expecting Cellect Biotechnology to pay a dividend over the next 12 months.

Have Cellect Biotechnology's shares ever split?

Cellect Biotechnology's shares were split on a 1:5 basis on 23 October 2019. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellect Biotechnology shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Cellect Biotechnology shares which in turn could have impacted Cellect Biotechnology's share price.

Cellect Biotechnology share price volatility

Over the last 12 months, Cellect Biotechnology's shares have ranged in value from as little as $0.4 up to $4.34. A popular way to gauge a stock's volatility is its "beta".

APOP.US volatility(beta: 1.94)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellect Biotechnology's is 1.9368. This would suggest that Cellect Biotechnology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cellect Biotechnology overview

Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. It is developing the ApoTainer selection kit, a shelf stem cell selection kit for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; and Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state. It also has a collaboration with the Washington University School of Medicine to determine the safety and tolerability of ApoGraft for bone marrow transplantations in the United States. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was founded in 2011 and is headquartered in Kfar Saba, Israel.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site